Informazioni sul prodotto
GLPG1690 is a potent, selective, and orally active small molecule that inhibits the signal transduction of colony-stimulating factor 1 receptor (CSF1R) and has been shown to be effective in treating autoimmune diseases. GLPG1690 is a novel small molecule that targets CSF1R, which is a key regulator of macrophage activation and fibrosis. This drug has been shown to ameliorate the effects of obesity on disease activity in mouse models of inflammatory bowel disease. The drug binds to the extracellular domain of CSF1R with high affinity and specificity. Preclinical studies have also shown that GLPG1690 inhibits matrix metalloproteinases (MMPs) as well as their activators. It has also been shown to inhibit the production of pro-inflammatory cytokines by monocytes, thereby reducing inflammation. GLPG1690 has been observed to be well tolerated in a Phase I clinical trial for psoriasis and psoriatic
Proprietà chimiche
Richiesta tecnica su: 3D-DQC26079 GLPG1690
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
